ArriVent BioPharma is a clinical-stage company developing oncology medicines, with an initial focus on solid tumors. Its lead candidate, firmonertinib (also known as furmonertinib), is an EGFR-targeted tyrosine kinase inhibitor advanced for non-small cell lung cancer, including underserved mutation subtypes. The pipeline also includes next-generation antibody-drug conjugates. The company has no commercial product revenue and serves the oncology development pathway rather than marketed drug sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -64.4 | — |
| Q2 2025 | 0 | — | -31.4 | — |
| Q3 2025 | 0 | — | -35 | — |
| Q4 2025 | 0 | — | -35.5 | — |
| Q1 2026 | 0 | — | -43.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Maze Therapeutics, Inc. (MAZE), Lakeland Financial Corporation (LKFN), InnovAge Holding Corp. (INNV), Schrödinger, Inc. (SDGR), Vistance Networks, Inc. (VISN), Immatics N.V. (IMTX)